Friday, 06 Dec 2019

You are here

RheumNow Podcast – Ghastly, Ghoulish News (10.31.19)

Dr. Jack Cush reviews recent journal articles and info bits from the past week on RheumNow.com. 

  1. Data on 14 261 PsA patients (from 11 European registries) startin TNFi therapy - shows that half (56%) were in DAS28 remission and 53% were ACR20 responders after 6 months, and 3/4 were still on TNFi at 1 year  http://bit.ly/2PzZKsQ
  2. Audio-recorded analysis of Rheum consultations & "shared-decision making" (SDM) scored 0-100. The mean wasn’t very good = 28.3 (SD=15.1). Higher SDM assoc w/ consultation duration, discussion of Rx start/stop/adjustments. Better visits take time & talk. http://bit.ly/2Wv0vVH 
  3. Claims analysis of psoriasis & PsA treated with inhibitors of TNF , IL-17 (SEC, IXE) or IL12/23 (UST) (2015-18) shows 2% of biologic starts had serious infections. SIE rates equal for TNFi & IL-17i; but were lower for IL-12/23 vs TNFi (HR=0.59; 0.39 -.90) https://t.co/YbNmEe19tS
  4. Metanalysis of multi‐biomarker disease activity (MBDA or Vectra) score & RA disease activity looked at 22 studies showing modest correlations w/ DAS28‐CRP (r 0.41) & DAS28‐ESR (r 0.48), but weaker correlations with SDAI, CDA (r 0.26) and RAPID3 (r 0.23) https://t.co/YjfU4TWGpQ
  5. Persistently frequent use of emergency department (ED) by lupus patients was primarily for pain by SLE pts who were more apt to be on narcotics. Pain management in SLE appears to be a significant challenge, if not unmet need. https://t.co/u9aM8pajZ8
  6. Study of 238 PsA patients starting a biologic shows that comparing those w/ comorbid FM vs without, PsA pts with FM had lower biologic survival (50% vs 74%) and PsA-FM unlikely to achieve remission (3.4% at 3mos and 0% at 6 months). https://t.co/29RAIEtGZA
  7. Metanalysis of 373 citations and 14 studies was unable to prove a protective X-ray benefit of TNF inhibitors in patients with axial spondyloarthritis. https://t.co/CSffpEEmHo
  8. Claims study of 253K csDMARD #RA showed switching to biologics/targeted synthetic DMARDs had increased risk of venous thromboembolism (HR 1.36 ;1.16, 1.58); Compared to 1st b/tsDMARDuse; VTE was higher for 1st (1.35) and 2nd b/tsDMARD switchers (1.48) https://t.co/9TnGpOwJga
  9. Common Physician HIPAA Violations   
  10. Frequent DMARD Discontinuations During Rheumatoid Pregnancies  
  11. Methotrexate and the Risk of Lung Disease  
Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

RheumNow Podcast - Monitoring Methotrexate Safety (12-6-19)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

#WomenInRheumatology: Is There a Speaker Gender Gap at ACR Meetings?

Recent studies have quantified the gender gap among speakers at academic conferences. The largest study of 181 medical conferences held in North America over one decade found an increase in the proportion of female speakers from 25 to 34% over time, and that the underrepresentation of women was more marked at surgical compared to medical conferences.

RheumNow Podcast –Favorites of ACR 2019 (11.22.19)

Dr. Jack Cush recaps standout presentations and information from ACR 2019 held in Atlanta November 9-12, 2019.

Hepatitis C-Related Cryoglobulinemic Vasculitis

Flares of vasculitis can still be a problem after hepatitis C-related cryoglobulinemic vasculitis patients are cured of their hepatitis C by direct-acting antivirals, as demonstrated by data from four registries presented at ACR 2019 in Atlanta, Georgia.

ACR 2019 - Report from Day One (Sunday)

Sunday was the first full day of scientific sessions at the 2019 ACR/ARP meeting in Atlanta. Yesterday we shared our initial news articles, videos and more with you. Following is my roundup of day one. 

Delays in Diagnosis